India, April 8 -- Drug major Sun Pharmaceutical Industries Ltd. on Monday said that INFUGEM™ (gemcitabine in sodium chloride injection), for intravenous use, is now commercially available in the U.S. INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the U.S. Food and Drug Administration (FDA) in July 2018 in combination with other drugs for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent for the treatment of pancreatic cancer, in a filing to Bombay Stock Exchange.
INFUGEM is an alcohol-free, clear, colorless, sterile solution of 10mg/mL gemcitabine in 0.9 per cent sodium chloride that is supplied to pharmacists in ready-to-infuse bags as...